| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 5 analysts have shared their insights on Bicycle Therapeutics (NASDAQ:BCYC), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.8, along with a high estimate of $55.00 and a low estimate of $28.00. A 6.21% drop is evident in the current average compared to the previous average price target of $43.50.
The standing of Bicycle Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Announces | Outperform | $35.00 | - |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $55.00 | $55.00 |
| Jay Olson | Oppenheimer | Maintains | Outperform | $48.00 | $48.00 |
| Ami Fadia | Needham | Maintains | Buy | $38.00 | $38.00 |
| Kalpit Patel | B. Riley Securities | Lowers | Neutral | $28.00 | $33.00 |
Capture valuable insights into Bicycle Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Bicycle Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Bicycle Therapeutics faced challenges, resulting in a decline of approximately -17.86% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bicycle Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -425.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Bicycle Therapeutics's ROE excels beyond industry benchmarks, reaching -6.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Bicycle Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.96%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BCYC
